DOI: https://doi.org/10.26641/2307-0404.2018.1.124953

Breast cancer and body weight index: the role of L-carnitine in prediction of answer to treatment and outcome of tumor in patients with obesity (review of literature).

M.I.M., Hojouj, I. N. Bondarenko, V. F. Zavizion, M. V. Artemenko, T. V. Hojouj, Yu. N. Bondarenko, N. E. Soloviova, Y. A. Shevchenko

Abstract


Increasing the effectiveness of antitumor therapy in breast cancer patients who take L-carnitine during preoperative systemic antitumor therapy compared with patients receiving standard neoadjuvant systemic antitumor therapy served as a prerequisite for studying possible antitumor mechanisms of L-carnitine. The positive effect of L-carnitine is due to the transfer of palm-n-fatty acid through the inner membrane into the mitochondrial matrix, which contributes to the formation of a significant number of ATP molecules. It has also been shown that L-carnitine can have a double protective effect, enhancing the energy dynamics of the cell and inhibiting the hyperexcitability of the cell membrane, making it an ideal tool for the prevention and treatment of complications of antitumor therapy and concomitant metabolic disorders. This work summarizes the results of epidemiological and clinical studies on the use of L-carnitine in the treatment of breast cancer.


Keywords


body mass index (BMI); breast cancer (BC); obesity; overall survival; L-carnitine

Full Text:

PDF

References


[Cancer in Ukraine. 2015-2016]. Byulleten Nat­sionalnogokantser-reestra Ukrainyi. Kyiv, 2017;18. Ukrainian.

Titov VN. [Functions of tochondria, carnitine, co­enzyme-a, fatty acids, glucose, Randla i insulin cycle (lec­ture)]. Klinicheskaya laboratornaya diagnostika. 2012;2:32-42. Russian.

Porter NS, Jason LA, Boulton A, Bothne N, Co­leman B. Alternative medical interventions used in the treatment and management of myalgic ence­pha­lomyelitis/chronic fatigue syndrome and fibromyalgia. J Altern. Complement Med. 2010;16(3):235-49.

Bhandari R, Kelley GA, Hartley T. Metabolic syn­drome is associated with increased breast cancer risk: a systematic review with meta-analysis. Int. J. Breast. Cancer. 2014;189384. doi: 10.1155/2014/189384

Chan DSM,VieiraAR, Aune D, Bandera EV, et.al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann. Oncol. 2014;25:1901-14. doi: 10.1093/annonc/mdu042

Bondarenko IN, Hojouj MIM. Body mass index as pro­gnostic feature in breast cancer. 2nd International Cancer Study & Therapy Conference is going to be held during at Embassy Suites.InnerHarbor,Baltimore,USA; 2017.

Bondarenko IN, Hojouj MIM. Body mass index as a prognostic feature in breast cancer. 14th World Cancer & Anti-Cancer Therapy Convention. 2016. doi: 10.4172. – 1948–5956.C1.094.

CampbellCI, Petrik JJ. Moorehead RA. ErbB2 enhances mammary tumorigenesis, oncogene-in­de­pendent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis. Mol. Cancer. 2010;9:35-250.

Rania M Khalil, Hoda A El-Bahrawy, Nahla E El- Ashmawy, Hossam Darwish. Carnitine Decreases Her-2 neu in Breast Cancer Patients Treated with Tamoxifen, IOSR. J Pharmacy Biological Sciences. 2013;5(I-2):91-98.

Doberenz j, Birkenfeld C, Kluge H, Eder K. Ef­fects of L-carnitine supplementation in pregnant sows on plasma concentrations of insulin-like growth factors, va­rious hormones and metabolites and chorion cha­racte­ris­tics. J. Anim. Physiol. Anim. Nutr. 2006;90:11(12):487-99.

[Internet]. Available from: http://kharkov.do­zor.ua/news/obwestvo/medicina/1183765.html

[Internet]. Available from: https://clinical­trials.gov/ct2/results?cond=Breast+Cancer&term=L-car­nitine&cntry=&state=&city=&dist=

[Internet]. Available from: https://clinical­trials.gov/ct2/show/NCT00754767?term=L-carnitine&cond­=Breast+Cancer&rank=1

[Internet]. Available from: http://www.who.int/me­diacentre/factsheets/fs311/ru/

Husain S, Crosson C.T. Role of PKCepsilon in PGF2alpha-stimulated MMP-2 secretion from human ciliary muscle cells. J. Ocul. Pharmacol. Ther. 2008;24:268-77.

Fontanella C, Lederer D, Gade S, M. Vanoppen, et al. Impact of body mass index on neoadjuvant treat­ment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast. Cancer Res. Treat. 2015;150:127-39.

JordanVC, O’Malley BW. Selective estrogen-re­ceptor modulators and antihormonal resistance in breast cancer. J Clin.Oncol. 2007;25:5815-24.

Kraemer WJ, Volek JS, Dunn-Lewis C. L-ca­rnitine supplementation: influence upon physiological function. Curr. Sports Med. Rep. 2008;7(4):218-23.

Sener G, Ekşioğlu-Demiralp E, Cetiner M, Ercan F. et al. L-Carnitine ameliorates methotrexateinduced oxidative organ injury and inhibits leukocyte death. Cell. Biol. Toxicol. 2006;22:47-60.

Chan HL, Chou HC, Duran M, J. Gruenewald, et al. Major role of epidermal growth factor receptor and Srckinases in promoting oxidative stress-dependent loss of adhesion and apoptosis in epithelial cells. J. Biol. Chem. 2010;285(7):4307-18.

Pajares B, Pollán M, Martín M, Mackey JR, et al. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes ac­cording to pathological subtypes: a pooled analysis. Breast. Cancer Res. 2013;15:105.

Sparano JF, Wang M, Zhao F, Stearns V, et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer. 2012;118:5937-46.

Neuhouser ML,AragakiAK, Prentice RL, Man­son J.E, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women’s health initiative randomized clinical trials. JAMA Oncol. 2015;1:611-21.

Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast. Cancer Res.Treat. 2010;123:627-35.

Arcangeli A, Crociani O, Lastraioli E, A. Masi, et al. Targeting ionchannels in cancer: a novel frontier in an­tineoplastic therapy. Curr. Med. Chem. 2009;16(1):66-93.


GOST Style Citations


  1. Рак в Украине, 2015-2016 // Бюл. нац. канцер-реестра Украины. – Киев,  2017. - № 18.
  2. Титов В.Н. Функция митохондрий, карнитин, коэнзим-а, жирные кислоты, глюкоза, цикл Рэндла и инсулин (лекция) / В.Н. Титов // Клинич. лаб. диаг­ностика. –  2012. – № 2. – С. 32–42.
  3. Alternative medical interventions used in the treatment and management of myalgic encephalo­myelitis/chronic fatigue syndrome and fibromyalgia / N.S. Porter, L.A. Jason, A. Boulton, N. Bothne, B. Cole­man // J. Altern. Complement Med. –2010. – Vol.16, N 3. – P. 235- 249.
  4. Bhandari R. Metabolic syndrome is associated with increased breast cancer risk: a systematic review with meta-analysis / R. Bhandari, G.A. Kelley, T. Hartley // Int. J. Breast. Cancer. – 2014. – P. 189384. doi: 10.1155/2014/189384
  5. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies / D.S.M. Chan, A.R Vie­ira, D. Aune, E.V. Bandera [et. al.] // Ann. Oncol. – 2014. – Vol. 25. – P. 1901–1914. doi: 10.1093/annonc/mdu042
  6. Bondarenko I. N. Body mass index as prognostic feature in breast cancer / I. N. Bondarenko, M. I. M. Ho­jouj // 2nd International Cancer Study & Therapy Con­ference is going to be held during  at Embassy Suites. –InnerHarbor,Baltimore,USA, 2017.
  7. Bondarenko I.N. Body mass index as a prognostic feature in breast cancer / I.N. Bondarenko, M.I.M. Hojouj // 14th World Cancer & Anti-Cancer Therapy Con­vention. – 2016. doi: 10.4172.–1948–5956.C1.094
  8. Campbell C. I. ErbB2 enhances mammary tumo­rigenesis, oncogene-independent recurrence and metas­tasis in a model of IGF-IR-mediated mammary tumo­rigenesis / C. I. Campbell, J. J. Petrik,  R. A. Moorehead // Mol. Cancer. – 2010. – Vol. 9. – P. 35-250.
  9. Carnitine Decreases Her-2 neu in Breast Cancer Patients Treated with Tamoxifen, IOSR / Rania M. Kha­lil, Hoda A. El-Bahrawy, Nahla E. El-Ashmawy, Hossam­Darwish // J. Pharmacy  Biological Sciences. – 2013. – Vol. 5,N I-2. – P. 91-98.
  10. Effects of L-carnitine supplementation in preg­nant sows on plasma concentrations of insulin-like growth factors, various hormones and metabolites and chorion characteristics / J. Doberenz, C. Birkenfeld, H. Kluge, K. Eder // J. Anim. Physiol. Anim. Nutr. – 2006. – Vol. 90, N 11-12. – P.487-499.
  11. http://kharkov.dozor.ua/news/obwestvo/medicina/1183765.html
  12. https://clinicaltrials.gov/ct2/results?cond=Breast+Cancer&term=L-carnitine&cntry=&state=&city=&dist=
  13. https://clinicaltrials.gov/ct2/show/NCT00754767?term=L-carnitine&cond=Breast+Cancer&rank=1
  14. http://www.who.int/mediacentre/factsheets/fs311/ru/
  15. Husain S. Role of PKCepsilon in PGF2alpha-sti­mulated MMP-2 secretion from human ciliary muscle cells / S. Husain, C. E. Crosson // J. Ocul. Pharmacol. Ther. – 2008. – Vol. 24, N 3. – P. 268-277.
  16. Impact of body mass index on neoadjuvant treat­ment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials / C. Fontanella, B. Le­de­rer, S. Gade, M. Vanoppen [et al.] // Breast. Cancer Res. Treat. – 2015. – Vol. 150. – P. 127-139.
  17. Jordan V. C. Selective estrogen-receptor modu­lators and antihormonal resistance in breast cancer / V.C. Jordan, B.W. O’Malley // J. Clin.Oncol. – 2007. – Vol. 25. – P. 5815-5824.
  18. Kraemer W. J. L-carnitine supplementation: inf­luen­ce upon physiological function / W.J. Kraemer, J.S. Vo­lek, C. Dunn-Lewis // Curr. Sports Med. Rep. – 2008. – Vol. 7, N 4. – P. 218-223.
  19. L-Carnitine ameliorates methotrexateinduced oxida­tive organ injury and inhibits leukocyte death / G. Sener, E. Ekşioğlu-Demiralp, M. Cetiner, F. Ercan [et al.] // Cell. Biol.Toxicol. – 2006. – Vol. 22, N1. – P. 47-60.
  20. Major role of epidermal growth factor receptor and Srckinases in promoting oxidative stress-dependent loss of adhesion and apoptosis in epithelial cells / H.L. Chan, H.C. Chou, M. Duran, J. Gruenewald [et al.] // J. Biol. Chem. –2010. – Vol. 285, N 7. – P. 4307-4318.
  21. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis / B. Pajares, M. Pollán, M. Martín, J.R. Mackey [et al.] // Breast. Cancer Res. – 2013. – Vol. 15. – R. 105.
  22. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer / J.F. Sparano, M. Wang, F. Zhao, V. Stearns [et al.] // Cancer. – 2012. – Vol.118. – P. 5937–46.
  23. Overweight, obesity, and postmenopausal in­vasive breast cancer risk: a secondary analysis of the women’s health initiative randomized clinical trials / M.L. Neuhouser, A.K. Aragaki, R.L. Prentice, J.E. Manson [et al.] // JAMA Oncol. – 2015. –N 1. – P. 611-621.
  24. Protani M. Effect of obesity on survival of wo­men with breast cancer: systematic review and meta-analysis / M. Protani, M. Coory , J.H. Martin // Breast. Can­cer Res.Treat. – 2010. – Vol. 123. – P. 627-635.
  25. Targeting ion channels in cancer: a novel frontier in antineoplastic therapy / A. Arcangeli, O. Crociani, E. Lastraioli, A. Masi [et al.] // Curr. Med. Chem. – 2009. – Vol. 16, N 1. – P. 66-93.




 

This work is licensed under a Creative Commons Attribution 4.0 International License